Accolade Inc
(STU:4NE1)
€
3.42
0.12 (3.64%)
Market Cap: 275.12 Mil
Enterprise Value: 279.28 Mil
PE Ratio: 0
PB Ratio: 0.70
GF Score: 61/100 Accolade Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023 / 05:35PM GMT
Release Date Price:
€11.9
(-2.46%)
Craig Matthew Hettenbach
Morgan Stanley, Research Division - VP
Great. Well, good afternoon, everyone. My name is Craig Hettenbach, I cover the digital health space at Morgan Stanley. I'm very pleased to have with us today Accolade and CFO, Steve Barnes.
Just before we get started, for important disclosures, please see the Morgan Stanley research disclosure website, www.morganstanley.com/researchdisclosures. So with that, Steve, again, thanks for being here today.
Questions & Answers
Craig Matthew Hettenbach
Morgan Stanley, Research Division - VP
I want to kind of kick off on the Analyst Day that you had in the spring. And just high level, you laid out targets of a 20% revenue CAGR. If we can just talk about what you see is driving the business and that type of growth? And certainly, we can dig into from there.
Stephen H. Barnes
Accolade, Inc. - CFO & Treasurer
That sounds great. And thank you very
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot